News

In this Vector report, research finds that drugs targeting the TP53 pathway can curb tumor cell proliferation in Ewing sarcoma.

A patient with a severe form of sickle cell disease is symptom-free after gene therapy knocks down BCL11A and restores fetal hemoglobin production.

The federal Beau Biden Cancer Moonshot program has awarded two grants of $2.5 million over five years to two research teams led by scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Kean will assume overall leadership in the program’s clinical practice and research in coordination with the Clinical Director, Leslie Lehmann, MD.

U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #3 in the nation in its new 2018-19 Best Children's Hospitals report.

Vector reports that scientists have discovered that DIPG/DMG tumors are made up of H3K27M-mutated cell populations that contain many cells stuck in a stem-cell-like state, fueling tumor growth.

Stuart H. Orkin, MD, an investigator of the Howard Hughes Medical Institute at Boston Children’s Hospital and Dana-Farber Cancer Institute and professor at Harvard Medical School known for his landmark discoveries into blood cell development and the genetic basis of blood disorders, is the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University.

Today, Stand Up To Cancer (SU2C), American Airlines and Marvel Studios’ Avengers: Infinity War announced a powerful collaboration as they team up in the fight against cancer.

In this Vector report, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reveal how the protein, BCL11A, controls the switch in the body’s production of fetal hemoglobin to adult hemoglobin.

Dana-Farber/Boston Children's is the only pediatric stem cell transplant center in the U.S. to exceed expected outcomes for allogeneic transplant patients in 2017.